EUSA buys up Innocoll antibiotic and pain control lines:
This article was originally published in Clinica
Executive Summary
Collagen implant technology developer Innocoll has sold its Collatamp G antibiotic surgical implant and wound dressing lines, as well as its CollaRx bupivacaine pain control implant, to specialty pharmaceutical company EUSA Pharma. The transaction sees Doylestown, Pennsylvania-based EUSA gain worldwide rights to the products, except in the US - although it does have an option to the US rights for CollaRx bupivacaine. Innocoll (Oxford, UK) will also transfer its European sales and marketing force (which sells to 20 European territories) and worldwide distribution network (covering 25 other non-European countries) to EUSA. Innocoll will continue to manufacture the products and supply them to EUSA, in return for an undisclosed upfront fee, future milestone payments, and an equity investment from the latter in Innocoll's parent company. Collatamp G is a biodegradable collagen sponge implant used in drug delivery, whereas CollaRx bupivacaine is designed to provide post-operative pain relief and reduce opioid dependency.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.